Clinical-stage biopharmaceutical company CytoMed Therapeutics (GDTC) entered into an at-the-market sales agreement with R.F. Lafferty & Co., as the sales agent.

Asia shares trade mixed on Tuesday as investors grew cautious over the ongoing Russia-Ukraine peace talks and upcoming ...

MPLX drives growth via strategic acquisitions, organic investments, and strong dividends (7.65% yield). Read here for an ...

Seanergy Maritime's daily breakeven rate gives it much wiggle room if rates were to drop. Read more on the Buy rating for ...

The Oncology Institute has achieved strong growth in revenue in the previous years. Click here to read more on TOI stock and ...

Hyatt (H) sees revenue growth but trails peers in profitability. With elevated debt and overvaluation, see why HLT & IHG ...

JPC's aggressive leverage and concentration in the financial sector increase risk, especially in a high interest rate ...

Dillard's saw encouraging sales momentum and improved category mix. See why we are upgrading DDS stock rating to hold.

Medical Properties Trust continues to struggle with tenant bankruptcies, declining revenues, and high debt. Read more on MPW ...

Clearwater Analytics Holdings delivered strong revenue growth, early synergy capture, and validated its front-to-back ...

Main Street Capital remains a strong BDC pick with resilient growth, optimal debt structure, and a stellar dividend track ...

Gold remains near record highs and royalty companies offer risk-insulated growth. See why miners are gaining favor amid ...